ATE544759T1 - 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon - Google Patents

5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon

Info

Publication number
ATE544759T1
ATE544759T1 AT08796320T AT08796320T ATE544759T1 AT E544759 T1 ATE544759 T1 AT E544759T1 AT 08796320 T AT08796320 T AT 08796320T AT 08796320 T AT08796320 T AT 08796320T AT E544759 T1 ATE544759 T1 AT E544759T1
Authority
AT
Austria
Prior art keywords
pyridinone
pharmaceutical compositions
substituted indazoles
indazoles
substituted
Prior art date
Application number
AT08796320T
Other languages
English (en)
Inventor
Peter Guzzo
Matthew David Surman
Alan John Henderson
Mark Hadden
Original Assignee
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Res Inc filed Critical Albany Molecular Res Inc
Application granted granted Critical
Publication of ATE544759T1 publication Critical patent/ATE544759T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08796320T 2007-07-21 2008-07-18 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon ATE544759T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95120107P 2007-07-21 2007-07-21
PCT/US2008/070535 WO2009015037A2 (en) 2007-07-21 2008-07-18 5-pyridinone substituted indazoles

Publications (1)

Publication Number Publication Date
ATE544759T1 true ATE544759T1 (de) 2012-02-15

Family

ID=40282093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08796320T ATE544759T1 (de) 2007-07-21 2008-07-18 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon

Country Status (12)

Country Link
US (1) US8273770B2 (de)
EP (1) EP2176251B1 (de)
JP (1) JP2010534248A (de)
KR (1) KR20100044225A (de)
CN (1) CN101861311A (de)
AT (1) ATE544759T1 (de)
AU (1) AU2008279321B2 (de)
BR (1) BRPI0814772A2 (de)
CA (1) CA2693377A1 (de)
ES (1) ES2382982T3 (de)
NZ (1) NZ582586A (de)
WO (1) WO2009015037A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0806537A2 (pt) 2007-01-10 2014-04-22 Albany Molecular Res Inc Indazóis substituídos por 5-piridinona
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
CA2850570A1 (en) * 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
CN107011283A (zh) * 2017-05-31 2017-08-04 湖南华腾制药有限公司 一种甲硫基取代苯并[d]恶唑衍生物的制备方法
US11242334B2 (en) 2017-08-22 2022-02-08 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CN112876458B (zh) * 2019-02-21 2022-10-04 厦门宝太生物科技股份有限公司 细胞程序性死亡-配体-1拮抗剂化合物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1A (en) 1836-07-13 John Ruggles Locomotive steam-engine for rail and other roads
US5225565A (en) 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
US5182403A (en) 1988-09-15 1993-01-26 The Upjohn Company Substituted 3(5'indazolyl) oxazolidin-2-ones
AU5194990A (en) 1989-02-23 1990-09-26 Rorer International (Holdings), Inc. Therapeutic aerosol formulations
US5393735A (en) 1990-08-09 1995-02-28 Rohm And Haas Company Herbicidal glutarimides
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
JPH03253852A (ja) 1990-03-05 1991-11-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法及び最終処理組成物
DE4017211A1 (de) 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
DE4018830A1 (de) 1990-06-12 1991-12-19 Langhals Heinz Synthese und verwendung von nicht-symmetrisch substituierten perylen-fluoreszenzfarbstoffen
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
DE4338784A1 (de) 1993-11-12 1995-05-18 Langhals Heinz Perylen-3,4-dicarbonsäureimide - neue hoch lichtechte Fluoreszenzfarbstoffe
TW279860B (de) 1993-11-12 1996-07-01 Ciba Geigy Ag
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
ZA966885B (en) 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
AU1592697A (en) 1995-08-22 1997-03-19 Du Pont Merck Pharmaceutical Company, The Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
AU7257096A (en) 1995-10-04 1997-04-28 Fmc Corporation Herbicidal 6-heterocyclic indazole derivatives
EP0801557B1 (de) 1995-10-12 2003-07-02 Supergen, Inc. Liposomformulierung von 5-beta steroiden
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
DE19651712A1 (de) 1996-12-12 1998-06-18 Langhals Heinz Pyrrolo- und Thiophenoperylenimide - stark fluoreszierende Heterocylen
BR9911031A (pt) 1998-05-20 2002-01-29 Liposome Co Inc Novas formulações em partìculas
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
EP1338272A1 (de) 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol Formulierungen für buccale und pulmonale Anwendung enthaltend Chenodeoxycholate oder Deoxycholate
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
BR0007974A (pt) 1999-02-03 2001-10-30 Powderject Res Ltd Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
CA2382821A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
MXPA02007052A (es) 2000-01-20 2002-12-13 Basilea Pharmaceutica Ag Composiciones que se administran nasalmente y que contienen peptidos ciclicos.
EP1129705A1 (de) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Pulverformulierung zur Inhalation
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
CA2406206C (en) 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DE10104279A1 (de) 2001-01-31 2002-08-01 Heinz Langhals Kompetitive Prionen-Reagenzien und ihre Anwendung in Diagnostik und Therapie
GB0107106D0 (en) 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
CZ20033053A3 (en) 2001-05-14 2004-05-12 Bristol@Myersásquibbápharmaácompany Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US20030019437A1 (en) 2001-07-26 2003-01-30 John Fore Ungulate game animal feed system and method
ES2307779T3 (es) 2001-08-16 2008-12-01 Baxter International Inc. Formulaciones de microparticulas a base de propelentes.
US6974869B2 (en) 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
AU2003230689B2 (en) 2002-03-20 2006-06-29 Alkermes, Inc. Inhalable sustained therapeutic formulations
CA2484724C (en) 2002-05-07 2007-01-16 Ferring B.V. Pharmaceutical formulations
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US20060194871A1 (en) 2003-04-11 2006-08-31 Barvian Kevin K Heterocyclic mchr1 antagoists
WO2004112719A2 (en) 2003-06-19 2004-12-29 Smithkline Beecham Corporation Chemical compounds
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CA2543122A1 (en) 2003-10-23 2005-05-12 Glaxo Group Limited 3-(4-aminophenyl) thienopyrimid-4-one derivatives as mch r1 antagonists for the treatment of obesity, diabetes, depression and anxiety
US7071182B2 (en) 2003-12-23 2006-07-04 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US7049307B2 (en) 2003-12-23 2006-05-23 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US20050137243A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
CN1930126A (zh) 2004-03-05 2007-03-14 万有制药株式会社 吡啶酮衍生物
DE602005027452D1 (de) 2004-05-07 2011-05-26 Memory Pharm Corp 1h-indazole, benzothiazole, 1,2-benzisoxazole, 1,2-benzisothiazole und chromone und deren herstellung und verwendungen
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
US20090264426A1 (en) * 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
BRPI0806537A2 (pt) 2007-01-10 2014-04-22 Albany Molecular Res Inc Indazóis substituídos por 5-piridinona
AU2008204915B2 (en) * 2007-01-10 2013-02-07 Albany Molecular Research, Inc. 5-furopyridinone substituted indazoles
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon

Also Published As

Publication number Publication date
JP2010534248A (ja) 2010-11-04
EP2176251B1 (de) 2012-02-08
EP2176251A2 (de) 2010-04-21
CN101861311A (zh) 2010-10-13
AU2008279321A1 (en) 2009-01-29
US8273770B2 (en) 2012-09-25
AU2008279321B2 (en) 2013-08-01
BRPI0814772A2 (pt) 2015-03-03
WO2009015037A3 (en) 2009-04-30
US20090082359A1 (en) 2009-03-26
HK1142608A1 (en) 2010-12-10
ES2382982T3 (es) 2012-06-15
NZ582586A (en) 2011-12-22
WO2009015037A2 (en) 2009-01-29
CA2693377A1 (en) 2009-01-29
KR20100044225A (ko) 2010-04-29

Similar Documents

Publication Publication Date Title
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
ATE502921T1 (de) Substituierte indole
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
ME01814B (me) Citotoksični agensi koji sadrže nove derivate tomaimicina i njihova terapeutska primjena
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
EA201170832A1 (ru) Пуриновые соединения
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
EP2133332A4 (de) (aza)indolderivat und seine verwendung für medizinische zwecke
EA200802008A1 (ru) Фармацевтические композиции
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
DK2170890T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
EA201000784A1 (ru) Антагонисты пути hedgehog и их терапевтические применения
ECSP10010722A (es) Compuestos orgánicos
ATE542799T1 (de) Chinolinonderivate als parp und tank-inhibitoren
EA201170227A1 (ru) Имидазолкарбоксамиды
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
NO20085338L (no) Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
UY32464A (es) Nuevos compuestos de indazol
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
MA32979B1 (fr) Derives aminoesterifies d'alcaloides et composition medicinale les incluant
EP2154966A4 (de) Benzimidazole und pharmazeutische zusammensetzungen daraus